{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:03:01Z","timestamp":1792508581342,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Recent advancements in imaging, particularly 18F-fluorodeoxyglucose positron-emission tomography\u2013computed tomography (FDG-PET\/CT), have improved the detection of involved lymph nodes, thus influencing staging accuracy and potentially treatment outcomes. This study is a\u00a0post hoc analysis of the GAZAI trial data to evaluate the impact of FDG-PET\/CT versus computed tomography (CT) alone on radiation target volumes for involved-site radiotherapy (IS-RT) in early-stage follicular lymphoma (FL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients in the GAZAI trial underwent pretherapeutic FDG-PET\/CT examinations, which were subject to central quality control. Lymph nodes with pathological metabolism were assessed for CT morphology. Differential regional involvement and the impact on radiation target volume for IS-RT were compared between PET\/CT-based to solely CT-based staging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 54\u00a0patients with PET-positive lymph nodes after initial surgery, 170 involved lymph nodes were identified in total. FDG-PET\/CT identified additionally involved lymph nodes not detected by CT in 61% of the patients, leading to a\u00a0significant change in radiation treatment fields for 30% of the cohort. Only 58% of all involved lymph nodes exhibited pathological CT morphology. The findings were robust across different Deauville score thresholds and CT morphological metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings confirm the essential role of FDG-PET\/CT in accurately defining the radiation volume for treatment of early-stage follicular lymphomas with radiotherapy. These results support the integration of FDG-PET\/CT into the standard diagnostic pathway and its inclusion in the service catalogue of statutory health insurance, emphasizing its importance for optimal treatment planning and the potential impact on patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-024-02356-x","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T07:50:45Z","timestamp":1736841045000},"page":"1137-1142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PET\/CT-based target volume definition in involved-site radiotherapy for treatment of early-stage nodal follicular lymphoma"],"prefix":"10.1007","volume":"201","author":[{"given":"Antje","family":"Wark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mavriopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"la Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Baues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6325-4193","authenticated-orcid":false,"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"29","key":"2356_CR1","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","volume":"36","author":"M MacManus","year":"2018","unstructured":"MacManus\u00a0M, Fisher\u00a0R, Roos\u00a0D, O\u2019Brien\u00a0P, Macann\u00a0A, Davis\u00a0S et\u00a0al (2018) Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J\u00a0Clin Oncol 36(29):2918\u20132925. https:\/\/doi.org\/10.1200\/JCO.2018.77.9892","journal-title":"J Clin Oncol"},{"issue":"3","key":"2356_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","volume":"133","author":"JL Brady","year":"2019","unstructured":"Brady\u00a0JL, Binkley\u00a0MS, Hajj\u00a0C, Chelius\u00a0M, Chau\u00a0K, Balogh\u00a0A et\u00a0al (2019) Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a\u00a0collaborative study by ILROG. Blood 133(3):237\u2013245. https:\/\/doi.org\/10.1182\/blood-2018-04-843540","journal-title":"Blood"},{"issue":"6","key":"2356_CR3","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","volume":"2","author":"K Herfarth","year":"2018","unstructured":"Herfarth\u00a0K, Borchmann\u00a0P, Schnaidt\u00a0S, Hohloch\u00a0K, Budach\u00a0V, Engelhard\u00a0M et\u00a0al (2018) Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR Study. Hemasphere 2(6):e160. https:\/\/doi.org\/10.1097\/HS9.0000000000000160","journal-title":"Hemasphere"},{"issue":"10","key":"2356_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00066-003-1062-8","volume":"179","author":"OJ Ott","year":"2003","unstructured":"Ott\u00a0OJ, Rodel\u00a0C, Gramatzki\u00a0M, Niedobitek\u00a0G, Sauer\u00a0R, Grabenbauer\u00a0GG (2003) Radiotherapy for stage\u00a0I\u2013III nodal low-grade non-Hodgkin\u2019s lymphoma. Strahlenther Onkol 179(10):694\u2013701. https:\/\/doi.org\/10.1007\/s00066-003-1062-8","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"2356_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling\u00a0M, Ghielmini\u00a0M, Rule\u00a0S, Salles\u00a0G, Ladetto\u00a0M, Tonino\u00a0SH et\u00a0al (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(3):298\u2013308. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","journal-title":"Ann Oncol"},{"issue":"5","key":"2356_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","volume":"107","author":"A Wirth","year":"2020","unstructured":"Wirth\u00a0A, Mikhaeel\u00a0NG, Aleman\u00a0BMP, Pinnix\u00a0CC, Constine\u00a0LS, Ricardi\u00a0U et\u00a0al (2020) Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines. Int J Radiat Oncol Biol Phys 107(5):909\u2013933. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.03.019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"2356_CR7","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1002\/cncr.25117","volume":"116","author":"BA Campbell","year":"2010","unstructured":"Campbell\u00a0BA, Voss\u00a0N, Woods\u00a0R, Gascoyne\u00a0RD, Morris\u00a0J, Pickles\u00a0T et\u00a0al (2010) Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 116(16):3797\u20133806. https:\/\/doi.org\/10.1002\/cncr.25117","journal-title":"Cancer"},{"issue":"2","key":"2356_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ijrobp.2009.07.1706","volume":"78","author":"JI Yu","year":"2010","unstructured":"Yu\u00a0JI, Nam\u00a0H, Ahn\u00a0YC, Kim\u00a0WS, Park\u00a0K, Kim\u00a0SJ (2010) Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B\u00a0cell lymphoma. Int J Radiat Oncol Biol Phys 78(2):507\u2013512. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.07.1706","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2356_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.radonc.2013.07.013","volume":"109","author":"MH Verhappen","year":"2013","unstructured":"Verhappen\u00a0MH, Poortmans\u00a0PM, Raaijmakers\u00a0E, Raemaekers\u00a0JM (2013) Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin\u2019s lymphoma. Radiother Oncol 109(1):133\u2013139. https:\/\/doi.org\/10.1016\/j.radonc.2013.07.013","journal-title":"Radiother Oncol"},{"issue":"5","key":"2356_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/annonc\/mdl014","volume":"17","author":"S Wohrer","year":"2006","unstructured":"Wohrer\u00a0S, Jaeger\u00a0U, Kletter\u00a0K, Becherer\u00a0A, Hauswirth\u00a0A, Turetschek\u00a0K et\u00a0al (2006) 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 17(5):780\u2013784. https:\/\/doi.org\/10.1093\/annonc\/mdl014","journal-title":"Ann Oncol"},{"issue":"8","key":"2356_CR11","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","volume":"24","author":"S Luminari","year":"2013","unstructured":"Luminari\u00a0S, Biasoli\u00a0I, Arcaini\u00a0L, Versari\u00a0A, Rusconi\u00a0C, Merli\u00a0F et\u00a0al (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a\u00a0retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24(8):2108\u20132112. https:\/\/doi.org\/10.1093\/annonc\/mdt137","journal-title":"Ann Oncol"},{"issue":"1","key":"2356_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","volume":"71","author":"A Wirth","year":"2008","unstructured":"Wirth\u00a0A, Foo\u00a0M, Seymour\u00a0JF, Macmanus\u00a0MP, Hicks\u00a0RJ (2008) Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 71(1):213\u2013219. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.09.051","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2356_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/biomedicines9050561","volume":"9","author":"IE Karsten","year":"2021","unstructured":"Karsten\u00a0IE, Reinartz\u00a0G, Pixberg\u00a0M, Kr\u00f6ger\u00a0K, Oertel\u00a0M, Friedrichs\u00a0B et\u00a0al (2021) Radiotherapy in follicular lymphoma staged by 18F-FDG-PET\/CT: a\u00a0German monocenter study. Biomedicines 9(5):561. https:\/\/doi.org\/10.3390\/biomedicines9050561","journal-title":"Biomedicines"},{"issue":"1","key":"2356_CR14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s13063-019-3614-y","volume":"20","author":"L Konig","year":"2019","unstructured":"Konig\u00a0L, Dreyling\u00a0M, Durig\u00a0J, Engelhard\u00a0M, Hohloch\u00a0K, Viardot\u00a0A et\u00a0al (2019) Therapy of nodal follicular lymphoma (WHO grade\u00a01\/2) in clinical stage\u00a0I\/II using response adapted involved site radiotherapy in combination with Obinutuzumab (Gazyvaro)\u2014GAZAI trial (GAZyvaro and response adapted involved-site radiotherapy): a\u00a0study protocol for a\u00a0single-arm, non-randomized, open, national, multi-center phase\u00a0II trial. Trials 20(1):544. https:\/\/doi.org\/10.1186\/s13063-019-3614-y","journal-title":"Trials"},{"issue":"27","key":"2356_CR15","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington\u00a0SF, Mikhaeel\u00a0NG, Kostakoglu\u00a0L, Meignan\u00a0M, Hutchings\u00a0M, Mueller\u00a0SP et\u00a0al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J\u00a0Clin Oncol 32(27):3048\u20133058. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229","journal-title":"J Clin Oncol"},{"issue":"6","key":"2356_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3322\/canjclin.55.6.368","volume":"55","author":"JO Armitage","year":"2005","unstructured":"Armitage\u00a0JO (2005) Staging non-Hodgkin lymphoma. CA Cancer J Clin 55(6):368\u2013376. https:\/\/doi.org\/10.3322\/canjclin.55.6.368","journal-title":"CA Cancer J Clin"},{"issue":"27","key":"2356_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson\u00a0BD, Fisher\u00a0RI, Barrington\u00a0SF, Cavalli\u00a0F, Schwartz\u00a0LH, Zucca\u00a0E et\u00a0al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J\u00a0Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"1","key":"2356_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","volume":"89","author":"T Illidge","year":"2014","unstructured":"Illidge\u00a0T, Specht\u00a0L, Yahalom\u00a0J, Aleman\u00a0B, Berthelsen\u00a0AK, Constine\u00a0L et\u00a0al (2014) Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89(1):49\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.01.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2356_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1055\/a-1525-7029","volume":"60","author":"C Lapa","year":"2021","unstructured":"Lapa\u00a0C, Nestle\u00a0U, Albert\u00a0NL, Baues\u00a0C, Beer\u00a0A, Buck\u00a0A et\u00a0al (2021) Value of PET imaging for radiation therapy. Nuklearmedizin 60(5):326\u2013343. https:\/\/doi.org\/10.1055\/a-1525-7029","journal-title":"Nuklearmedizin"},{"issue":"2","key":"2356_CR20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2007-07-101899","volume":"111","author":"TC Kwee","year":"2008","unstructured":"Kwee\u00a0TC, Kwee\u00a0RM, Nievelstein\u00a0RA (2008) Imaging in staging of malignant lymphoma: a\u00a0systematic review. Blood 111(2):504\u2013516. https:\/\/doi.org\/10.1182\/blood-2007-07-101899","journal-title":"Blood"},{"issue":"8","key":"2356_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00066-020-01624-w","volume":"196","author":"L Konig","year":"2020","unstructured":"Konig\u00a0L, Herfarth\u00a0K, Horner-Rieber\u00a0J, Dietrich\u00a0S, Wiegel\u00a0T, Debus\u00a0J et\u00a0al (2020) Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma. Strahlenther Onkol 196(8):705\u2013714. https:\/\/doi.org\/10.1007\/s00066-020-01624-w","journal-title":"Strahlenther Onkol"},{"key":"2356_CR22","first-page":"36","volume":"189","author":"M Engelhard","year":"2013","unstructured":"Engelhard\u00a0M, Unterhalt\u00a0M, Hansmann\u00a0ML, Stuschke\u00a0M, Indole\u00a0R\u2011TN (2013) Follicular lymphoma: final results of the randomized evaluation of curative radiotherapy in limited stage nodal disease. Strahlenther Onkol 189:36","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2356_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijrobp.2015.01.048","volume":"92","author":"J Kriz","year":"2015","unstructured":"Kriz\u00a0J, Reinartz\u00a0G, Dietlein\u00a0M, Kobe\u00a0C, Kuhnert\u00a0G, Haverkamp\u00a0H et\u00a0al (2015) Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 92(1):46\u201353. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.048","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2356_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.radonc.2017.05.014","volume":"124","author":"D Bird","year":"2017","unstructured":"Bird\u00a0D, Patel\u00a0C, Scarsbrook\u00a0AF, Cosgrove\u00a0V, Thomas\u00a0E, Gilson\u00a0D et\u00a0al (2017) Evaluation of clinical target volume expansion required for involved site neck radiotherapy for lymphoma to account for the absence of a\u00a0pre-chemotherapy PET-CT in the radiotherapy treatment position. Radiother Oncol 124(1):161\u2013167. https:\/\/doi.org\/10.1016\/j.radonc.2017.05.014","journal-title":"Radiother Oncol"},{"issue":"4","key":"2356_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1080\/0284186X.2017.1279750","volume":"56","author":"MC Aznar","year":"2017","unstructured":"Aznar\u00a0MC, Girinsky\u00a0T, Berthelsen\u00a0AK, Aleman\u00a0B, Beijert\u00a0M, Hutchings\u00a0M et\u00a0al (2017) Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group. Acta Oncol 56(4):608\u2013613. https:\/\/doi.org\/10.1080\/0284186X.2017.1279750","journal-title":"Acta Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02356-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02356-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:41:04Z","timestamp":1761154864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02356-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2356"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02356-x","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Wark, J.-Y.\u00a0Kim, E.\u00a0Mavriopoulou, C.\u00a0la Foug\u00e8re, T.\u00a0Wiegel, C.W.\u00a0Scholz, C.\u00a0Baues, M.\u00a0Li, T.\u00a0Gauler, S.E.\u00a0Combs, and K.\u00a0Herfarth declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}